


PHARMACEUTICAL 2020

Monopar Therapeutics

Monopar Therapeutics Rank 104 of 362



RealRate

PHARMACEUTICAL 2020



Monopar Therapeutics Rank 104 of 362

The relative strengths and weaknesses of Monopar Therapeutics are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Monopar Therapeutics compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 392% points. The greatest weakness of Monopar Therapeutics is the variable Net Income, reducing the Economic Capital Ratio by 61% points.

The company's Economic Capital Ratio, given in the ranking table, is -47%, being 256% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	13,230
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	724
Liabilities, Non-Current	0
Other Assets	122
Other Compr. Net Income	-8.6
Other Expenses	0
Other Liabilities	0
Other Net Income	99
Property and Equipment	0
Research and Development	1,969
Revenues	0
Selling, General and Administrative Expense	2,355

Output Variable	Value in 1000 USD
Assets	13,352
Liabilities	724
Expenses	4,324
Stockholders Equity	12,628
Net Income	-4,225
Comprehensive Net Income	-4,229
Economic Capital Ratio	-47%